Estimated Reading Time: 8 minutes
This analysis is brought to you by Inkwood Research, a market intelligence firm specializing in precision medicine, molecular diagnostics, and oncology technology ecosystems. Our research team tracks biomarker-driven drug development, regulatory pathways for in vitro diagnostic devices, and pharma-diagnostic co-development partnerships across North America, Europe, and Asia-Pacific. Through engagement with diagnostic developers, laboratory networks, and regulatory consultants, we deliver actionable intelligence for stakeholders navigating the global companion diagnostics market.
TL;DR
Companion diagnostics have quietly become the gatekeeper of modern cancer treatment. Without the right test, the right drug never reaches the right patient. According to our analysis, the global companion diagnostics market has expanded at a 18.45% CAGR in recent years, propelled by rising cancer incidence, a widening targeted therapy pipeline, and deeper pharma-diagnostic collaboration. Meanwhile, regulators have broadened the definition of what a companion test can be — and that shift is redrawing competitive lines across precision oncology.
Who Will Find This Blog Useful?
Diagnostic executives, pharmaceutical strategy leaders, and laboratory directors will find direct relevance here. Additionally, investment analysts tracking molecular diagnostics, regulatory affairs professionals managing in vitro diagnostic device submissions, and oncology commercial teams planning biomarker testing rollouts will gain practical intelligence on competitive positioning, recent approvals, and where the next growth pockets are emerging.
Table of Contents
- What Exactly Is a Companion Diagnostic?
- What Is Driving the Global Companion Diagnostics Market?
- How Is Regulation Reshaping Companion Diagnostics?
- Which Companies Lead the Companion Diagnostics Market?
- What Are the Latest Developments in Biomarker Testing?
- What Should Decision-Makers Do Next?
- Key Takeaways
- Frequently Asked Questions
What Exactly Is a Companion Diagnostic?
Start with the regulator’s own words. The U.S. Food and Drug Administration describes a companion diagnostic as a medical device — often an in vitro device — that provides information essential for the safe and effective use of a corresponding drug or biological product. In practice, that makes the test inseparable from the therapy it supports.
How the Test and the Drug Travel Together
Because the pairing is formal, the companion diagnostic appears in the drug’s own labeling. Consequently, a prescription cannot proceed cleanly without a matching authorized test. That single design choice explains why pharmaceutical companies now build diagnostic partnerships into early clinical planning rather than bolting them on at launch.
Three functions define the category:
- Patient selection — identifying who is likely to respond to a specific targeted therapy
- Risk management — flagging patients facing elevated adverse-event risk
- Treatment monitoring — tracking response or residual disease during therapy
Notably, that third function was largely theoretical until recently. Today it is approved practice, and it has opened an entirely new revenue lane within the global companion diagnostics market.
What Is Driving the Global Companion Diagnostics Market?
Growth here is not abstract. It follows directly from how oncology drugs are now designed, trialed, and reimbursed. Based on our analysis, the Global Companion Diagnostics market has compounded at 18.45% in recent years, and the underlying drivers show little sign of cooling.
The Demand Engine Behind Biomarker Testing
Several forces converge at once:
- Rising cancer incidence, which enlarges the addressable testing population year after year
- A deepening targeted therapy pipeline, since each new biomarker-linked drug creates fresh demand for a paired test
- The shift toward personalized medicine, where treatment decisions increasingly hinge on molecular profile rather than tumor site alone
- Expanding clinical trial activity, which relies on molecular diagnostics for enrollment and stratification
- Co-development economics, as drug and diagnostic partners share regulatory timelines and commercial risk
Why Competitive Intensity Keeps Climbing
Here is where it gets interesting. Many companion diagnostics are functionally undifferentiated — several assays can detect the same mutation with comparable performance. Therefore, competition shifts to breadth of portfolio, speed of approval, and depth of pharma relationships. Firms with wide test menus and established co-development agreements consistently capture disproportionate share.
How Is Regulation Reshaping Companion Diagnostics?
Regulatory architecture is not background noise in this market. Rather, it determines which products reach clinicians and how quickly.
A Quiet but Telling Rename
In July 2026, the FDA republished its reference table as the List of FDA-Authorized Companion Diagnostic Devices. Previously, the list was titled for cleared or approved devices only. The revised wording reflects that entries now arrive through several routes:
- Premarket approval (PMA)
- 510(k) clearance
- De Novo classification
- Humanitarian device exemption
Small change, meaningful signal. Broader pathways generally mean lower barriers for novel test formats.
What Authorization Actually Covers
Authorization is drug-specific unless a test carries a group labeling indication, which the agency tracks separately for defined groups of oncology therapeutics. Consequently, a test approved for one therapy does not automatically extend to another. For commercial teams, that nuance drives everything from label strategy to payer negotiation. Moreover, insurers and oncologists both reference this list directly, so inclusion carries real economic weight.
Which Companies Lead the Companion Diagnostics Market?
Rather than a single hierarchy, the competitive landscape splits into distinct strategic groups. Each group competes on a different axis.
Integrated Pharma-Diagnostic Players
- Roche Diagnostics — headquartered in Basel, Switzerland, and paired with Roche’s own oncology pipeline. Its strength spans PCR, immunohistochemistry, and in situ hybridization assays, supported by Foundation Medicine’s sequencing portfolio.
- Abbott Laboratories — the Illinois-based firm operates across molecular and core diagnostics, with growth driven by product launches, collaborations, and acquisitions.
Platform and Sequencing Specialists
- Thermo Fisher Scientific — the Massachusetts-headquartered group anchors its position on the Oncomine next-generation sequencing franchise, deployed across clinical labs worldwide.
- Illumina — the San Diego company supplies the sequencing infrastructure underpinning much of the industry’s NGS-based biomarker testing.
- QIAGEN — the Netherlands-domiciled firm, with major operations in Hilden, Germany, competes through its therascreen PCR assays and extensive pharma co-development agreements.
Focused Molecular Diagnostics Innovators
- Myriad Genetics — the Salt Lake City company built its position on hereditary cancer and homologous recombination deficiency testing.
- Exact Sciences — now home to the Oncotype DX franchise following its acquisition of Genomic Health, it focuses on treatment-decision testing in breast and colon cancer.
- Guardant Health and Natera — both compete on blood-based approaches, a segment expanding faster than tissue testing.What Are the Latest Developments in Biomarker Testing?What Are the Latest Developments in Biomarker Testing?
The past year delivered approvals that genuinely changed the category’s boundaries. Each one tells you something about where investment is heading.
Liquid Biopsy Crosses a Threshold
In May 2026, Natera announced FDA approval of Signatera CDx for use with adjuvant atezolizumab in muscle-invasive bladder cancer. Significantly, this marked the first companion diagnostic approval in blood-based molecular residual disease testing. The test does not predict response to a mutation-targeted drug. Instead, it detects residual disease and guides whether treatment is needed at all.
Shortly afterward, Guardant Health reported FDA approval of Guardant360 CDx for AstraZeneca’s camizestrant in HR-positive, HER2-negative advanced breast cancer. Notably, the approval recommends repeat testing every three months to catch emerging ESR1 mutations before progression appears on imaging. Recurring testing changes the revenue model considerably.
Tissue Testing Keeps Opening New Targets
- Roche received FDA approval in June 2026 for the VENTANA PTEN (SP218) RxDx Assay — the first IHC companion diagnostic for PTEN loss in prostate adenocarcinoma, paired with AstraZeneca’s capivasertib.
- Roche also secured expanded approval in August 2026 for its PATHWAY HER2 (4B5) and VENTANA HER2 Dual ISH tests in metastatic gastroesophageal adenocarcinoma.
- Thermo Fisher obtained FDA approval in November 2025 for the Oncomine Dx Target Test as a companion diagnostic for Bayer’s sevabertinib in HER2-mutated non-small cell lung cancer.
What Should Decision-Makers Do Next?
Strategy in this market rewards sequencing decisions correctly. Our research points to four priorities:
- Lock in co-development early. Contemporaneous drug and diagnostic approval closes access gaps at launch, and late diagnostic planning routinely delays commercial uptake.
- Build for repeat testing. Monitoring indications generate recurring volume, whereas one-time selection tests do not.
- Treat reimbursement as product design. Coverage breadth determines real-world accessibility more than analytical performance does.
- Widen the biomarker menu. Undifferentiated single-marker assays face steady price pressure; multi-biomarker panels defend margin far more effectively.
Key Takeaways
- Companion diagnostics function as regulatory gatekeepers, because the FDA ties each authorized test to specific therapeutic labeling.
- Our analysis places recent growth in the global companion diagnostics market at 18.45% CAGR, driven by targeted therapy expansion and personalized medicine adoption.
- The FDA’s 2026 list rename reflects broader authorization routes, including De Novo classification and 510(k) clearance.
- Blood-based testing crossed a major threshold with the first MRD companion diagnostic approval in bladder cancer.
- Competitive advantage now rests on portfolio breadth, pharma partnerships, and recurring-testing indications rather than single-assay performance.
Conclusion
Companion diagnostics have moved from supporting act to structural necessity in oncology. Regulatory pathways are widening, liquid biopsy is maturing, and monitoring indications are creating durable revenue streams that did not exist a few years ago. For diagnostic developers, pharmaceutical partners, and investors alike, the strategic question is no longer whether to participate — it is where along the value chain to build.
Inkwood Research provides the market intelligence and competitive analysis needed to answer that question with confidence. Connect with our team to explore how our insights can support your positioning in the global companion diagnostics market.
Frequently Asked Questions
What is a companion diagnostic?
It is a medical device, usually an in vitro test, providing information essential for the safe, effective use of a specific drug.
Why is the companion diagnostics market growing quickly?
Rising cancer incidence, expanding targeted therapy pipelines, and pharma-diagnostic co-development agreements together sustain demand for biomarker testing worldwide.
What changed in companion diagnostics recently?
Blood-based molecular residual disease testing received its first FDA companion diagnostic approval in 2026, extending the category beyond mutation-based patient selection.
